Your browser doesn't support javascript.
loading
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri, Timothy P; Zhao, Ming; Evans, Kurt W; Varadarajan, Kaushik; Moss, Tyler; Scott, Stephen; Kahle, Michael P; Byrnes, Charnel C; Chen, Huiqin; Lee, Sunyoung S; Halim, Abdel-Baset; Hirai, Hiroshi; Wacheck, Volker; Kwong, Lawrence N; Rodon, Jordi; Javle, Milind; Meric-Bernstam, Funda.
Afiliação
  • DiPeri TP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Zhao M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Varadarajan K; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Moss T; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Scott S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Kahle MP; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Byrnes CC; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Chen H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Halim AB; Taiho Oncology, Inc., Preston NJ, United States.
  • Hirai H; Taiho Oncology, Inc., Preston NJ, United States.
  • Wacheck V; Taiho Oncology, Inc., Preston NJ, United States.
  • Kwong LN; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston TX, United States; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston TX, United States.
  • Javle M; Taiho Oncology, Inc., Preston NJ, United States.
  • Meric-Bernstam F; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, United States; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston TX, United States. Electronic address: fmeric@mdanderson.org.
J Hepatol ; 80(2): 322-334, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37972659
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article